Alcidion Group

Alcidion Group Debt/EBITDA

The Total Debt to EBITDA Ratio of Alcidion Group (ALC.AX) as of Nov 11, 2026 is 0.32. In the previous year, Total Debt to EBITDA Ratio was 0.11 — a change of 181.51% (higher).

Debt/EBITDA

0.32

YoY

181.51%

Last updated:

Total Debt to EBITDA Ratio of Alcidion Group is 2026 0.32 . Total Debt to EBITDA Ratio of Alcidion Group was 2025 0.11 . It decreases by 181.51% higher compared to the previous year.

The Alcidion Group Debt/EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Debt/EBITDA
Date
Debt/EBITDA
Jan 1, 2019
-63.30 AUD
Jan 1, 2020
-0.15 AUD
Jan 1, 2021
0.64 AUD
Jan 1, 2022
-1.54 AUD
Jan 1, 2023
-1.40 AUD
Jan 1, 2024
-0.38 AUD
Jan 1, 2025
0.11 AUD
Jan 1, 2026
0.32 AUD
The Alcidion Group Debt/EBITDA history
YEARDebt/EBITDAYoY
0.32+181.51%
0.11-130.05%
-0.38-73.08%
-1.40-9.36%
-1.54-341.53%
0.64-519.28%
-0.15-99.76%
-63.30+14,434.04%
-0.44+11.77%
-0.39+19,947.19%
-0.00-99.95%
-3.95—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Alcidion Group Stock analysis

What does Alcidion Group do? Alcidion Group Ltd. generates revenue through the development and licensing of its healthcare software products, including Miya Precision, Miya Observations, Flow, Task Management, and PAS, marketed under the Miya brand. The company also resells selected healthcare software from strategic partners and provides implementation, support, maintenance, and data analysis services to healthcare customers in Australia, New Zealand, and the United Kingdom. Its flagship product Miya Precision, a FHIR-event platform-based solution, supports clinical and operational applications, while Smartpage offers hospital communication and task management via smartphone and web. The firm serves over 400 hospitals across its key markets. Miya Precision and its associated modules form the core of Alcidion's product portfolio, targeting hospitals seeking integrated clinical solutions. Smartpage, Patientrack, and Silverlink PCS complement these offerings, catering to diverse healthcare communication and operational needs. The company’s revenue streams are driven by direct sales of software licenses, ongoing service contracts, and partner resales, with a focus on the Australian, New Zealand, and UK healthcare sectors. Alcidion’s business model emphasizes software licensing and service delivery, with Miya Precision as the primary revenue generator. The company’s strategic partnerships enable it to resell third-party software, expanding its product range without additional development costs. Healthcare institutions in Australia, New Zealand, and the United Kingdom are the primary buyers, leveraging Alcidion’s solutions for improved clinical workflows and operational efficiency. Alcidion Group is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Alcidion Group stock

Total Debt to EBITDA Ratio of Alcidion Group is 0.32 in 2026.

Total Debt to EBITDA Ratio of Alcidion Group changed from 0.11 to 0.32, representing a 181.51% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Total Debt to EBITDA Ratio Alcidion Group since 2006 – with annual values, charts, and detailed analysis.

Debt/EBITDA measures total debt relative to earnings before interest, taxes, depreciation, and amortization. It indicates the years needed to repay all debt from EBITDA.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Total Debt to EBITDA Ratio's Alcidion Group with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Alcidion Group

All Key Metrics — Alcidion Group